Spruce Bio slips as genetic disorder drug fails mid-stage study in adults

Spruce Biosciences

13/03/2024 21:50

** Shares of Spruce Biosciences  SPRB.O  fall 74.6% to $1.32
after the bell    
    ** Co says its experimental drug to treat congenital adrenal
hyperplasia (CAH) failed to meet the main goal of mid-stage
study conducted in certain adult patients 
    ** CAH is a group of genetic disorders that affect adrenal
glands, which produce hormones
    ** The drug candidate, tildacerfont, did not significantly
reduce androstenedione levels in CAH patients with high
concentrations of this sex hormone precursor
    ** Tildacerfont is being tested in another mid-stage study
in certain adult patients where data is expected in Q3 2024
-SPRB
    ** Up to last close, stock up ~78% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))